The Defense Health Agency (DHA) issues updated clinical guidance that expands a hormone-screening pathway to include female service members. The guidance directs health-care providers to screen women on an annual basis for hormonal dysregulation.
All three outlets describe the update as a change in screening procedures rather than a new treatment, emphasizing that the guidance creates a defined pathway for providers. The reporting notes that the DHA is setting expectations for routine screening, including how often women are assessed.
While Air Force Times, Military Times, and Navy Times all cover the same core policy details—annual screening and a focus on hormonal dysregulation—they do not significantly diverge in their descriptions of the policy’s purpose or implementation. The articles agree that the DHA is expanding existing hormone-screening guidance to cover female personnel, affecting how clinicians manage screening recommendations going forward.
